Hemorrhage caused by antiangiogenic therapy within previously irradiated areas: Expected consequence of tumor shrinkage or a warning for antiangiogenic agents combined to radiotherapy?

Annals of Oncology

Volumn 22, Issue 6, 2011, Pages 1247-1249

  Soria, J C ^a,b   Deutsch, E ^a,b  

^a University Paris South   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CETUXIMAB; DOXORUBICIN; GEMCITABINE; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLACEBO; SORAFENIB; SUNITINIB; THROMBOPLASTIN; VASCULOTROPIN; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ARTERIAL HEAD BLEEDING; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD VESSEL INJURY; BRAIN HEMORRHAGE; CANCER MORTALITY; CANCER RADIOTHERAPY; CLINICAL PRACTICE; CLINICAL RESEARCH; CONTINUOUS INFUSION; DIGESTIVE SYSTEM PERFORATION; DRUG BIOAVAILABILITY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; ENTERITIS; EPISTAXIS; ERYTHEMA; FIBROSIS; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HEAD AND NECK TUMOR; HEMATEMESIS; HUMAN; INFLAMMATION; INTERSTITIAL LYMPHEDEMA; INTESTINE PERFORATION; LUNG HEMORRHAGE; LYMPHEDEMA; META ANALYSIS (TOPIC); MOLECULARLY TARGETED THERAPY; NASOPHARYNX CARCINOMA; NECK BLEEDING; NECROSIS; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIATION RECALL SYNDROME; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN DISEASE; SKIN EROSION; SKIN ULCER; TUMOR NECROSIS; VOMITING; WOUND HEALING IMPAIRMENT; XEROSTOMIA; CHEMICALLY INDUCED; FEMALE; HEMOPTYSIS; MALE; NASOPHARYNGEAL NEOPLASMS;

ANTINEOPLASTIC AGENTS; FEMALE; HEMATEMESIS; HEMOPTYSIS; HUMANS; INDOLES; MALE; NASOPHARYNGEAL NEOPLASMS; PYRROLES;

EID: 79957839457     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq775     Document Type: Editorial

References (25)

1. Hui EP, Ma BBY, King AD et al. Hemorrhagic complications in a phase 2 study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high dose radiation. Ann Oncol 2011; 22: 1280-1287.
2. Chen YF, Lo YC, Lin WC et al. Transarterial embolization for control of bleeding in patients with head and neck cancer. Otolaryngol Head Neck Surg 2010; 142(1): 90-94.
3. Pereira J, Phan T. Management of bleeding in patients with advanced cancer. Oncologist 2004; 9(5): 561-570.
4. Huvos AG, Leaming RH, Moore OS. Clinicopathologic study of the resected carotid artery. Analysis of sixty-four cases. Am J Surg 1973; 126(4): 570-574.
5. Swain RE, Biller HF, Ogura JH, Harvey JE. An experimental analysis of causative factors and protective methods in carotid artery rupture. Arch Otolaryngol 1974; 99(4): 235-241.
6. Toyoda T, Sawatari K, Yamada T et al. Endovascular therapeutic occlusion following bilateral carotid artery bypass for radiation-induced carotid artery blowout: case report. Radiat Med 2000; 18(5): 315-317.
7. Wong SJ, Machtay M, Li Y. Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? J Clin Oncol 2006; 24(17): 2653-2658.
8. Ch'ang HJ, Maj JG, Paris F et al. ATM regulates target switching to escalating doses of radiation in the intestines. Nat Med 2005; 11(5): 484-490.
9. Je Y, Schutz FA, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009; 10(10): 967-974.
10. Schutz FA, Je Y, Azzi GR et al. Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Ann Oncol 2010 Nov 29 [Epub ahead of print], doi:10.1093/annonc/ mdq587.
11. Johnson DH, Fehrenbacher L, Novotny WF et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22(11): 2184-2191.
12. Machiels JP, Henry S, Zanetta S et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol 2010; 28(1): 21-28.
13. Williamson SK, Moon J, Huang CH et al. Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420. J Clin Oncol 2010; 28(20): 3330-3335.
14. Lordick F, Geinitz H, Theisen J et al. Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases. Int J Radiat Oncol Biol Phys 2006; 64(5): 1295-1298.
15. Abdollahi A, Schwager C, Kleeff J et al. Transcriptional network governing the angiogenic switch in human pancreatic cancer. Proc Natl Acad Sci U S A 2007; 104(31): 12890-12895.
16. Blumenschein GR Jr., Gatzemeier U, Fossella F et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009; 27(26): 4274-4280.
17. Stewart FA, Hoving S, Russell NS. Vascular damage as an underlying mechanism of cardiac and cerebral toxicity in irradiated cancer patients. Radiat Res 2010 Aug 30 [Epub ahead of print].
18. Zips D, Eicheler W, Geyer P et al. Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition. Cancer Res 2005; 65(12): 5374-5379.
19. Deshaies I, Malka D, Soria JC et al. Antiangiogenic agents and late anastomotic complications. J Surg Oncol 2010; 101(2): 180-183.
20. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7(6): 475-485.
21. Antoun S, Baracos VE, Birdsell L et al. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010; 21(8): 1594-1598.
22. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24(1): 25-35.
23. Law AB, Junor EJ. Chemotherapy-induced recall of cetuximab and radiation skin reaction. Clin Oncol (R Coll Radiol) 2009; 21(1): 77-78.
24. Saif MW, Ramos J, Knisely J. Radiation recall phenomenon secondary to bevacizumab in a patient with pancreatic cancer. JOP 2008; 9(6): 744-747.
25. Bourgier C, Moldovan C, Soria JC, Deutsch E. mTOR inhibitors induced recall of radiation reaction. Ann Oncol 2011; in press.